Biologic therapies for chronic obstructive pulmonary disease

References

• Lange P, Ahmed E, Lahmar ZM, et al. Natural history and mechanisms of COPD. Respirology. 2021;26:298–321.
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54:1900651.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18:454–466.
   PubMed Web of Science ®Google Scholar
• Higham A, Beech A, Wolosianka S, et al. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. Allergy. 2021;76:1861–1864.
   PubMed Web of Science ®Google Scholar
• Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184:1469–1485.
   PubMed Web of Science ®Google Scholar
• Chiu CJ, Huang MT. Asthma in the precision medicine era: biologics and probiotics. Int J Mol Sci. 2021;22:4528.
   PubMed Web of Science ®Google Scholar
• Fieldes M, Bourguignon C, Assou S, et al., Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Res. 2021. 7(2): 00437–2020.
   PubMedGoogle Scholar
• David B, Bafadhel M, Koenderman L, et al., Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021. 76(2): 188–195.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Martinez FJ, et al. Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 review. Am J Respir Crit Care Med. 2022;206(1):17–24.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Ora J, et al. Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers. Mol Diagn Ther. 2019;23(5):603–614.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564.
   PubMed Web of Science ®Google Scholar
• Bel EH, Ten Brinke A. New anti-eosinophil drugs for asthma and COPD: targeting the trait! Chest. 2017;152:1276–1282.
   PubMed Web of Science ®Google Scholar
• Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J. 2006;27(2):293–299.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold? Semin Respir Crit Care Med. 2015;36:508–522.
   PubMed Web of Science ®Google Scholar
• Gea J. The future of biological therapies in COPD. Arch Bronconeumol. 2018;54(4):185–186.
   PubMed Web of Science ®Google Scholar
• Le Rouzic O, Pichavant M, Frealle E, et al. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J. 2017;50(4):1602434.
   PubMed Web of Science ®Google Scholar
• Roos AB, Sandén C, Mori M, et al. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med. 2015;191(11):1232–1241.
   PubMed Web of Science ®Google Scholar
• Roos AB, Mori M, Gura HK, et al. Increased IL-17RA and IL-17RC in end-stage COPD and the contribution to mast cell secretion of FGF-2 and VEGF. Respir Res. 2017;18(1):48.
   PubMedGoogle Scholar
• Zou Y, Chen X, Liu J, et al. Serum IL-1ß and IL-17 levels in patients with COPD: associations with clinical parameters. Int J Chron Obstruct Pulmon Dis. 2017;12:1247–1254.
   PubMed Web of Science ®Google Scholar
• Ritzmann F, Beisswenger C. Preclinical studies and the function of IL-17 cytokines in COPD. Ann Anat. 2021;237:151729.
   PubMed Web of Science ®Google Scholar
• Ding F, Han L, Fu Q, et al. IL-17 aggravates Pseudomonas aeruginosa airway infection in acute exacerbations of chronic obstructive pulmonary disease. Front Immunol. 2022;12:811803.
   PubMedGoogle Scholar
• Vella G, Ritzmann F, Wolf L, et al. IL-17C contributes to NTHi-induced inflammation and lung damage in experimental COPD and is present in sputum during acute exacerbations. PLoS One. 2021;16(1):e0243484.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84.
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD. 2017;14(5):476–483.
   PubMedGoogle Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• Khokhlovich E, Grant S, Kazani S, et al. The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients [abstract]. Eur Respir J. 2017;50(suppl61):OA2897.
   Google Scholar
• Kirsten A, Watz H, Pedersen F, et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers. Eur Respir J. 2013;41(1):239–241.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, et al. An overview of the safety and eficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biologics. 2021;15:363–374.
   PubMed Web of Science ®Google Scholar
• Li Y, Hua S, Mechanisms of pathogenesis in allergic asthma: role of interleukin-23. Respirology. 2014;19(5):663–669.
   PubMed Web of Science ®Google Scholar
• Fujii U, Miyahara N, Taniguchi A, et al. IL-23 is essential for the development of elastase-induced pulmonary inflammation and emphysema. Am J Respir Cell Mol Biol. 2016;55(5):697–707.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Nair P, Cousins DJ, et al. Risankizumab in severe asthma - a phase 2a, placebo-controlled trial. N Engl J Med. 2021;385(18):1669–1679.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, et al. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;31:15–27.
   PubMed Web of Science ®Google Scholar
• Fu JJ, McDonald VM, Baines KJ, et al. Airway IL-1β and systemic inflammation as predictors of future exacerbation risk in asthma and COPD. Chest. 2015;148(3):618–629.
   PubMed Web of Science ®Google Scholar
• Singh B, Arora S, Khanna V, Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis. 2010;73(2):86–87.
   PubMedGoogle Scholar
• Rogliani P, Matera MG, Puxeddu E, et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018;50:28–37.
   PubMed Web of Science ®Google Scholar
• Osei ET, Brandsma CA, Timens W, et al. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J. 2020;55(2):1900563.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Bracke K, Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(5):S322–328.
   PubMedGoogle Scholar
• Mukaida N, Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2003;284(4):L566–577.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–934.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40(3):724–741.
   PubMed Web of Science ®Google Scholar
• Adage T, Del Bene F, Fiorentini F, et al. PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation. Cytokine. 2015;76(2):433–441.
   PubMed Web of Science ®Google Scholar
• Gerlza T, Hecher B, Jeremic D, et al. A combinatorial approach to biophysically characterize chemokine-glycan binding affinities for drug development. Molecules. 2014;19(7):10618–10634.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M, TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2010;23(2):121–128.
   PubMed Web of Science ®Google Scholar
• Zhu NL, Li C, Huang HH, et al. TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells. Gene. 2007;393(1–2):70–80.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou J, Diao X, et al. Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2019;13:1753466619866096.
   Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomized double-blind controlled trial. Thorax. 2013;68(2):142–148.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Hudson M, TNF-alpha antagonists and the prevention of hospitalization for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234–238.
   PubMed Web of Science ®Google Scholar
• Dejager L, Dendoncker K, Eggermont M, et al. Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 2015;8(6):1212–1225.
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Karaman M, Bagriyanik HA, et al. Comparison of TNF antagonism by etanercept and dexamethasone on airway epithelium and remodeling in an experimental model of asthma. Int Immunopharmacol. 2013;17(3):768–773.
   PubMed Web of Science ®Google Scholar
• Guilleminault L, Conde E, Reber LL Pharmacological approaches to target type 2 cytokines in asthma. Pharmacol Ther. 2022;237:108167.
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Speer T, Herr C et al, IgE is associated with exacerbations and lung function decline in COPD. Respir Res. 2022;23(1):1.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Chipps BE, Griffin NM, et al. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629–1633.e2.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in treating eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16(2):186–200.
   PubMed Web of Science ®Google Scholar
• Eltboli O, Mistry V, Barker B, et al. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670.
   PubMed Web of Science ®Google Scholar
• Caramori G, Adcock IM, Di Stefano A, et al. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412.
   PubMed Web of Science ®Google Scholar
• Donovan T, Milan SJ, Wang R et al, Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12(12):CD013432.
   PubMed Web of Science ®Google Scholar
• Yousuf A, Ibrahim W, Greening NJ, et al. T2 Biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7(5):1405–1416.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chapman KR, Bafadhel M et al, Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–1770.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D et al, Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):158–170.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, RA P Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901.
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175.
   PubMed Web of Science ®Google Scholar
• Shankar A, McAlees JW, Lewkowich IP, Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol. 2022;150(2):266–276.
   PubMed Web of Science ®Google Scholar
• Saco TV, Pepper A, Casale TB, Uses of biologics in allergic diseases: What to choose and when. Ann Allergy Asthma Immunol. 2018;120(4):357–366.
   PubMed Web of Science ®Google Scholar
• Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019;53(5):1801291.
   PubMed Web of Science ®Google Scholar
• Sun J, Liu T, Yan Y, et al. The role of Th1/Th2 cytokines played in regulation of specific CD4+ Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. Scand J Immunol. 2018;88(1):e12674.
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, et al. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155.
   PubMedGoogle Scholar
• Corren J, Ziegler SF, TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603–1609.
   PubMed Web of Science ®Google Scholar
• Borowski A, Vetter T, Kuepper M, et al. Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain. Cytokine. 2013;61(2):546–555.
   PubMed Web of Science ®Google Scholar
• Mkorombindo T, Balkissoon R, Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease. Chronic Obstr Pulm Dis. 2022;9(2):285–297.
   PubMed Web of Science ®Google Scholar
• Zhang K, Shan L, Rahman MS, et al. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L375–382.
   PubMed Web of Science ®Google Scholar
• Redhu NS, Gounni AS, Function and mechanisms of TSLP/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2012;42(7):994–1005.
   PubMed Web of Science ®Google Scholar
• Calvén J, Yudina Y, Hallgren O, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4(1):86–99.
   PubMed Web of Science ®Google Scholar
• Elder MJ, Webster SJ, Williams DL, et al. TSLP production by dendritic cells is modulated by IL-1β and components of the endoplasmic reticulum stress response. Eur J Immunol. 2016;46(2):455–463.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. TSLP inhibitors for asthma: current status and future prospects. Drugs. 2020;80(5):449–458.
   PubMed Web of Science ®Google Scholar
• Hohlfeld J, Gauvreau GM, Boulet LP, et al. Efficacy of CSJ117 on allergen-induced asthmatic response in mild atopic asthma patients. Pneumologie. 2021;75(Suppl. 1):S33.
   PubMedGoogle Scholar
• Gabryelska A, Kuna P, Antczak A, et al. IL-33 Mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692.
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–37.
   PubMed Web of Science ®Google Scholar
• Donovan C, Hansbro PM, IL-33 in chronic respiratory disease: from preclinical to clinical studies. ACS Pharmacol Transl Sci. 2019;3(1):56–62.
   PubMedGoogle Scholar
• Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L619–627.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Celli BR, Wechsler ME et al, Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288–1298.
   PubMed Web of Science ®Google Scholar
• Yousuf AJ, Mohammed S, Carr L et al, Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022;10(5):469–477.
   PubMed Web of Science ®Google Scholar
• Singh D, IL-33 in COPD: the hunt for responder subgroups. Lancet Respir Med. 2022;10(5):425–426.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Rogliani P, et al. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs. 2016;76(13):1257–1270.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355.
   PubMed Web of Science ®Google Scholar
• Nucera F, Lo Bello F, Shen SS, et al. Role of atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD. Curr Med Chem. 2021;28(13):2577–2653.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Annibale R, et al. Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol. 2021;14(8):1015–1027.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al., Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:F1000 Faculty Rev-1533
   PubMedGoogle Scholar
• McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019;53(5):1802058.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG et al, Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab. Br J Pharmacol. 2020;177(20):4750–4765.
   PubMed Web of Science ®Google Scholar
• Manson ML, Säfholm J, James A, et al. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145(3):808–817.e2.
   PubMed Web of Science ®Google Scholar